13th ASM Conference on Candida and Candidiasis

 描述(申请人提供)：念珠菌是人类的主要真菌病原体，可引起从口腔和阴道念珠菌病到危及生命的念珠菌症和侵袭性疾病。念珠菌研究界专注于与流行病学、耐药性、感染、宿主反应和治疗学相关的广泛主题。两年一度的念珠菌和念珠菌病会议是介绍这些不同领域的前沿进展和最新观点的主要论坛。请求为2016年4月13日至17日在华盛顿州西雅图举行的第13届念珠菌和念珠菌病会议提供部分支持。这次会议部分是由美国微生物学会赞助的，该学会提供管理专业知识和资金支持。该计划以过去的会议为基础，可靠地吸引了大约400名美国和国际科学家，并在参与者调查中得到了热情的支持。该计划包括17个会议，每个部分有5到6名演讲者。至少68场演讲将根据提交的摘要进行选择。每届会议的主席都是根据他们在该主题领域的专门知识挑选出来的。这一安排提供了灵活性，以展示前沿进展，并招募各种新兴和老牌演讲者。平行会议将讨论感染模型、新陈代谢适应、真菌药物相互作用和新技术，同时鼓励富有成效的互动和讨论。“电梯演讲”将允许初级科学家在舞台上用几分钟的时间总结他们的海报。三个下午的海报会议将允许讨论250-350张海报。有关念珠菌病的流行病学、诊断和治疗的临床讲座将纳入重点关注念珠菌感染的关键方面的会议，包括环境信号、抗真菌药物和耐药性以及免疫识别。在关于念珠菌病例报告的单独会议上，临床医生将向基础科学家通报诊断和治疗不同类型感染的挑战。我们相信，我们将实现我们的会议目标--介绍该领域的最新进展，突出初级科学家(特别是妇女和少数族裔)的成就，促进协同和跨学科互动，并提供一个供社区广泛讨论的场所。

 DESCRIPTION (provided by the applicant): Candida is the major fungal pathogen of humans, causing diseases that range from oral and vaginal candidiasis to life-threatening candidemia and invasive disease. The Candida research community focuses on a broad spectrum of subjects that relate to epidemiology, drug resistance, infection, host response, and therapeutics. The biennial Candida and Candidiasis Conference is the premier forum for presentation of cutting-edge advances and the latest perspectives in these diverse areas. Funds are requested for partial support for the 13th Conference on Candida and Candidiasis, to be held April 13 - 17, 2016, in Seattle, WA. The conference is sponsored in part by the American Society for Microbiology, which provides both management expertise and financial support. The Program is based upon past conferences, which reliably draw approximately 400 U.S. and International scientists, and have been met with enthusiastic support in participant surveys. The Program includes 17 sessions, with 5 or 6 speakers in each section. At least 68 of the talks will be selected based on submitted abstracts. Chairs for each session have been selected for their expertise in the subject area. This arrangement provides flexibility to present cutting-edge advances and to enlist a diverse spectrum of emerging and established speakers. Parallel sessions will address infection models, metabolic adaptation, fungal drug interactions and new technologies while encouraging productive interaction and discussion. "Elevator talks" will allow junior scientists to summarize their poster in a few minutes on stage. Three afternoon poster sessions will allow discussion of the 250-350 posters. Clinical talks about the epidemiology, diagnosis, and treatment of candidiasis will be incorporated into sessions that focus on key aspects of Candida infections, including environmental signaling, antifungal agents and resistance, and immune recognition. In a separate session on Candida case reports, clinicians will inform basic scientists about the challenges of diagnosing and treating different types of infection. We are confident that we will achieve our meeting goals - to present the latest advances in the field, to spotlight achievements of junior scientists (especially women and minorities), to promote synergistic and interdisciplinary interactions, and to provide a venue for community-wide discussion.